The Comparative Efficacy Of Anthracycline And Cisplatin Versus Traditional EP Chemotherapy In Extensive-stage Small Cell Lung Cancer

Objective:Today, lung cancer (LC) has become one of the malignant tumors which have the highest morbidity and mortality, and has become a serious threat to human health and quality of life. How to prevent and treat lung cancer better becomes one of the main tasks of scientific research in the world. Small Cell Lung Cancer (SCLC), which is one of the highest degree of malignancy in lung cancer, is considered as the scientific research and issues of many researchers. The clinical treatment of SCLC include radiation therapy (referred to as radiotherapy) and chemotherapy (referred to as chemotherapy), and the EP chemotherapy is considered as the standard treatment in current treatment. Although the response rate and the recurrence rate are high (> 80% and 75% -80%), the second-line treatment results are poor, so looking for a considerable new program to extend the efficacy of disease-free survival in patients with the EP program is urgent. Anthracycline antitumor drugs is a common clinical medicine. Compared with traditional medicines, whether if it has a better efficacy and greater safety need a large number of clinical trial data to be determined.The trial was to compare the efficacy and the security of anthracycline and the traditional EP chemotherapy in extensive small cell lung cance.Methods:According to the WHO classification of small cell lung cancer,we selected 24 untreated extensive small cell lung cancer cases,17 of them are males, 7 are females, age between 20 to 75 years old. They have seperated into two groups dynamic randomly, and one group used anthracycline ? cisplatin (AP) program while the other used traditional EP (etoposide ? cisplatin) program. We tested the size of the primary tumor lesions, observed the symptoms and signs of patients regularly. And used lung CT, abdominal ultrasonography, echocardiography, dynamic ultrasound and routine blood and biochemical examination to assessment of treatment effects, safety and effectiveness. On group data are analyzed with statistical significance.Results:After 6 cycles of chemotherapy, we compared the results of the two groups of patients who have the extensive small cell lung cancer. The reduction rate of primary tumor is basically the same between AP group and EP group, the difference is not statistically significant (P> 0.05). Hematologic toxicity occurred less in AP group than in EP group, and there is significant (P <0.05). Cardiac toxicity occurred at a same level between AP group and EP group, is not significant (P> 0.05).But the symptoms and signs of improvement is faster in AP group than in EP group, the incidence of serious adverse events is less in AP group than in EP group , and the difference is statistically significant (P <0.05).Conclusion:For the initial treatment of extensive small cell lung cancer, anthracycline drugs in combination with cisplatin compared to conventional EP program was better in patients. But because of limited number of cases and observations , a large number of clinical trial still need to be done to prove that he conclusion is true and the efficacy is better.